| 1 |
Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system
Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli et al. · Plant Biotechnology Journal
Open access |
24 May 2007 |
433 |
| 2 |
The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily
Lewis F. Neville, Guenther Mathiak, Omar Bagasra · Cytokine & Growth Factor Reviews
Review |
Sep 1997 |
357 |
| 3 |
Small interfering RNA Inhibits Hepatitis B virus replication in mice
Hilla Giladi, Mali Ketzinel‐Gilad, Ludmila Rivkin et al. · Molecular Therapy
Open access |
Nov 2003 |
308 |
| 4 |
Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
Ari Zimran et al. · Blood
Open access |
7 Sep 2011 |
210 |
| 5 |
Large‐scale production of pharmaceutical proteins in plant cell culture—the protalix experience
Yoram Tekoah, Avidor Shulman, Tali A. Kizhner et al. · Plant Biotechnology Journal
Open access |
23 Jun 2015 |
193 |
| 6 |
Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology
Gregory Alex Grabowski, Myriam Golembo, Yoseph Shaaltiel · Molecular Genetics and Metabolism
|
2 Mar 2014 |
155 |
| 7 |
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial
Raphael Schiffmann et al. · Journal of Inherited Metabolic Disease
Open access |
5 Mar 2019 |
141 |
| 8 |
Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease
Tali A. Kizhner, Yaniv Azulay, Mariana Hainrichson et al. · Molecular Genetics and Metabolism
Open access |
10 Aug 2014 |
130 |
| 9 |
Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β-Glucosidase
Boris Brumshtein, Harry M. Greenblatt, Terry D. Butters et al. · Journal of Biological Chemistry
Open access |
31 Jul 2007 |
122 |
| 10 |
Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study
Thomas D. Schiano, Michael Charlton, Zobair M. Younossi et al. · Liver Transplantation
|
2006 |
117 |
| 11 |
Establishment of a tobacco BY2 cell line devoid of plant‐specific xylose and fucose as a platform for the production of biotherapeutic proteins
Uri Hanania, Tami Ariel, Yoram Tekoah et al. · Plant Biotechnology Journal
Open access |
3 Feb 2017 |
111 |
| 12 |
Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients
Rachel Eren et al. · Journal of Virology
Open access |
24 Feb 2006 |
102 |
| 13 |
Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems
Yoram Tekoah, Salit Tzaban, Tali A. Kizhner et al. · Bioscience Reports
Open access |
29 Aug 2013 |
100 |
| 14 |
The Hepatitis B Virus-Trimera Mouse: A Model for Human Hbv Infection and Evaluation of Anti–Hbv Therapeutic Agents
Ehud Ilan, Tatjana Burakova, Shlomo Dagan et al. · Hepatology
Open access |
Feb 1999 |
98 |
| 15 |
The Hepatitis C Virus (HCV)–Trimera Mouse: A Model for Evaluation of Agents against HCV
Ehud Ilan, Joseph Arazi, Ofer Nussbaum et al. · The Journal of Infectious Diseases
|
15 Jan 2002 |
93 |
| 16 |
Preclinical Evaluation of Two Human Anti-Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees
Rachel Eren, Ehud Ilan, Ofer Nussbaum et al. · Hepatology
Open access |
Sep 2000 |
84 |
| 17 |
Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells†
Avidan Uriel Neumann, S M Phillips, Idit Levine et al. · Hepatology
Open access |
27 May 2010 |
81 |
| 18 |
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
Zachary David Crees et al. · Nature Medicine
Open access |
Apr 2023 |
79 |
| 19 |
Plant specific N-glycans do not have proven adverse effects in humans
Yoseph Shaaltiel, Yoram Tekoah · Nature Biotechnology
|
Jul 2016 |
71 |
| 20 |
Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease
Yoseph Shaaltiel, Svetlana Gingis‐Velitski, Salit Tzaban et al. · Plant Biotechnology Journal
Open access |
Apr 2015 |
71 |
| 21 |
Caspase‐1‐inhibitor ac‐YVAD‐cmk reduces LPS‐lethality in rats without affecting haematology or cytokine responses
Guenther Mathiak, Guido Grass, Thomas Herzmann et al. · British Journal of Pharmacology
Open access |
Oct 2000 |
66 |
| 22 |
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase
Gregory M. Pastores, Milan S. Petakov, Pilar Giraldo et al. · Blood Cells Molecules and Diseases
|
18 Jun 2014 |
60 |
| 23 |
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story
Bonita J. Rup, Sari Alon, Bat-Chen Amit-Cohen et al. · PLoS ONE
Open access |
31 Oct 2017 |
55 |
| 24 |
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
Eric L Wallace et al. · Journal of Medical Genetics
Open access |
8 Nov 2023 |
49 |
| 25 |
6‐Amino‐6‐deoxy‐5,6‐di‐ N ‐( N ′‐octyliminomethylidene)nojirimycin: Synthesis, Biological Evaluation, and Crystal Structure in Complex with Acid β‐Glucosidase
Boris Brumshtein, Matilde Aguilar‐Moncayo, M. Isabel García‐Moreno et al. · ChemBioChem
|
13 May 2009 |
48 |
| 26 |
The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases
Yaīr Reisner, Shlomo Dagan · Trends in biotechnology
Review |
Jun 1998 |
44 |
| 27 |
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase
Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov et al. · Blood Cells Molecules and Diseases
Open access |
20 Oct 2016 |
43 |
| 28 |
HUWE1 ubiquitinates MyoD and targets it for proteasomal degradation
Tahel Noy, Oded Suad, Daniel Taglicht et al. · Biochemical and Biophysical Research Communications
|
19 Jan 2012 |
41 |
| 29 |
Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: Safety and antiviral activity
Eithan Galun, Norah A. Terrault, Rachel Eren et al. · Journal of Hepatology
Open access |
21 Oct 2006 |
41 |
| 30 |
Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease
Ilya Ruderfer, Avidor Shulman, Tali A. Kizhner et al. · Bioconjugate Chemistry
|
26 Apr 2018 |
40 |
| 31 |
Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease
Laura van Dussen, Ari Zimran, Erik M. Akkerman et al. · Blood Cells Molecules and Diseases
|
28 Nov 2012 |
38 |
| 32 |
Cell-Based and Animal Models for Hepatitis B and C Viruses
Raymond F. Schinazi, Ehud Ilan, Paul L. Black et al. · Antiviral chemistry & chemotherapy
Open access |
Jun 1999 |
36 |
| 33 |
Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model
Yoav Barnea, Yehuda Carmeli, Lewis F. Neville et al. · Burns
|
Nov 2008 |
35 |
| 34 |
Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease
Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov et al. · Blood Cells Molecules and Diseases
Open access |
7 Nov 2014 |
35 |
| 35 |
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Aleš Linhart, Gabriela Dostálová, Kathy Nicholls et al. · Orphanet Journal of Rare Diseases
Open access |
21 Oct 2023 |
34 |
| 36 |
Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection
Lewis F. Neville, Yoav Barnea, Orly Hammer-Münz et al. · International Journal of Molecular Medicine
|
Jul 2005 |
33 |
| 37 |
Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues
Boris Brumshtein, Matilde Aguilar‐Moncayo, Juan Manuel Benito et al. · Organic & Biomolecular Chemistry
Open access |
2011 |
32 |
| 38 |
Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
Gregory M. Pastores, Suma P. Shankar, Milan S. Petakov et al. · American Journal of Hematology
Open access |
22 Apr 2016 |
29 |
| 39 |
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease
Derralynn A. Hughes, Derlis Gonzalez, Gustavo H. B. Maegawa et al. · Genetics in Medicine
Open access |
24 Aug 2023 |
28 |
| 40 |
Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease
Ari Zimran, Gloria Durán, Pilar Giraldo et al. · Blood Cells Molecules and Diseases
Open access |
18 Jul 2016 |
28 |
| 41 |
GENESIS: Phase III Trial Evaluating BL-8040 + G-CSF to Mobilize Hematopoietic Cells for Autologous Transplant in Myeloma
Zachary David Crees, Keith E Stockerl-Goldstein, Abi Vainstein et al. · Future Oncology
Open access |
9 Sep 2019 |
25 |
| 42 |
Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
Ari Zimran, Gloria Durán, Atul B Mehta et al. · American Journal of Hematology
Open access |
19 Mar 2016 |
24 |
| 43 |
Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model
Luc Bracoud, Harris Ahmad, Einat Brill‐Almon et al. · Blood Cells Molecules and Diseases
|
18 Nov 2010 |
23 |
| 44 |
Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis
Yaron Ilan, Ami Ben Yaʼacov, Yehudit Shabbat et al. · World Journal of Gastroenterology
Open access |
2016 |
22 |
| 45 |
Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R
Jacob Atsmon, Einat Brill‐Almon, Carmit Nadri-Shay et al. · Toxicology and Applied Pharmacology
|
6 Jun 2015 |
20 |
| 46 |
CHEMOKINES AND INTERLEUKIN-18 ARE UP-REGULATED IN BRONCHOALVEOLAR LAVAGE FLUID BUT NOT IN SERUM OF SEPTIC SURGICAL ICU PATIENTS
Guenther Mathiak, Lewis F. Neville, Guido Grass et al. · Shock
|
Mar 2001 |
19 |
| 47 |
The use of the hydrodynamic HBV animal model to study HBV biology and anti-viral therapy
Mali Ketzinel‐Gilad, Arie Zauberman, Ofer Nussbaum et al. · Hepatology Research
|
8 Mar 2006 |
18 |
| 48 |
Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
Zachary David Crees, Michael P. Rettig, Asad Bashey et al. · Blood Advances
Open access |
16 Jun 2023 |
17 |
| 49 |
A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
Myrl D. Holida, Aleš Linhart, Antonio Pisani et al. · Journal of Inherited Metabolic Disease
Open access |
9 Oct 2024 |
16 |
| 50 |
Nonlinear focusing of DNA macromolecules
Leonid L. Frumin, Sergey Evgenyevich Peltek, Gleb V. Zilberstein · Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics
|
17 Jul 2001 |
15 |